NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
1 Assignment
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
4 Citations
31 Claims
-
1. (canceled)
-
2. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprises;a heavy chain variable region that comprises at least one amino acid in the specified position selected from the group consisting of T30, S31, Y32, G33, W50, S52, F53, Y54, N55, N57, N59, R98, G99, Y100, and G101, as numbered sequentially in the direction from the amino terminus to the carboxy terminus of the heavy chain; and a light chain variable region. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11)
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
-
12. A pharmaceutical composition comprising:
-
a pharmaceutically acceptable carrier; and a monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues;
S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprises;
a heavy chain variable region that comprises at least one amino acid in the specified position selected from the group consisting of T30, S31, Y32, G33, W50, S52, F53, Y54, N55, N57, N59, R98, G99, Y100, and G101, as numbered sequentially in the direction from the amino terminus to the carboxy terminus of the heavy chain; and
a light chain variable region.
-
-
13. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein said monoclonal antibody comprises;a heavy chain variable region; and a light chain variable region that comprises at least one amino acid selected from the group consisting of G30, G31, Y32, N33, S34, E52, Y93, T94, S95, T96, and S97, as numbered sequentially in the direction from the amino terminus to the carboxy terminus of the light chain.
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
-
14. A monoclonal antibody that binds to a PCSK9 protein comprising SEQ ID NO:
- 1 and inhibits the binding interaction of PCSK9 to LDLR, wherein said monoclonal antibody comprises;
a heavy chain variable region that comprises at least one amino acid selected from the group consisting of T30, S31, Y32, G33, W50, S52, F53, Y54, N55, N57, N59, R98, G99, Y100, and G101, as numbered sequentially in the direction from the amino terminus to the carboxy terminus of the heavy chain; and a light chain variable region. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
- 1 and inhibits the binding interaction of PCSK9 to LDLR, wherein said monoclonal antibody comprises;
Specification